Improvement of hemodynamics with the ADVOS Therapy

Improvement of hemodynamics with the ADVOS Therapy - ADVODYNAMICS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031279

Enrollment

Registered

2023-03-06

Start date

2023-03-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical ill patients in the ICU

Interventions

Group 1: Observational prospective register study. Screening of patients should be performed 12-0 h prior to the use of ADVOS therapy. Subsequently, blood is drawn 6-0 h prior to the use of ADVOS ther

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Indication for multiorgan support with ADVOS therapy

Exclusion criteria

Exclusion criteria: Age < 18 years Pregnancy Contraindication for ADVOS therapy Moribund patient (life expectancy < 24 hours)

Design outcomes

Primary

Measure	Time frame
Composite outcome of acid-base balance correction and reduction of catecholamine dose after three consecutive 24-hour ADVOS sessions	—

Secondary

Measure	Time frame
Reduction in serum lactate levels Reduction in cytokine levels (IL-6, IL-10) Changes in regional oxygen saturation (rSO2) (through in-vivo optical spectroscopy: i.e., INVOS system) Hemodynamic changes during connection to and disconnection from the ADVOS multi (through Transpulmonary Thermodilution: i.e., PiCCO) Feasibility of ultrafiltration (% of patients reaching 80% of the target fluid removal) Improvement of pulmonary edema and capillary leak (i.e., reduction of EVLWI and PVPI) Removal of water-soluble and protein-bound substances (e.g., bilirubin, creatinine, BUN) ICU-LOS 28-day, ICU- and Hospital-Mortality	—

Measure

Time frame

Reduction in serum lactate levels Reduction in cytokine levels (IL-6, IL-10) Changes in regional oxygen saturation (rSO2) (through in-vivo optical spectroscopy: i.e., INVOS system) Hemodynamic changes during connection to and disconnection from the ADVOS multi (through Transpulmonary Thermodilution: i.e., PiCCO) Feasibility of ultrafiltration (% of patients reaching 80% of the target fluid removal) Improvement of pulmonary edema and capillary leak (i.e., reduction of EVLWI and PVPI) Removal of water-soluble and protein-bound substances (e.g., bilirubin, creatinine, BUN) ICU-LOS 28-day, ICU- and Hospital-Mortality

—

Countries

Germany

Contacts

Public ContactTim- Philipp Simon

Uniklinik RWTH Aachen

tsimon@ukaachen.de+492418036374

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026